bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors
September 20 2017 - 8:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company
committed to developing potentially transformative gene therapies
for severe genetic diseases and T cell-based immunotherapies for
cancer, today announced that it has appointed Mary Lynne Hedley,
Ph.D. to its Board of Directors.
“I’m thrilled to welcome Mary Lynne to the Board,” said Nick
Leschly, chief bluebird. “Since founding TESARO in 2010, she has
shepherded that company from a clinical stage to a commercial
stage, and has experience in bringing novel therapies to patients
in need. As we continue to progress our four clinical programs, her
broad executive experience, from clinical research through
operations and commercialization, will be an invaluable resource
for the growing bluebird team.”
“bluebird bio is a clear leader in the development of gene
therapies for patients with severe genetic diseases, and has shown
tremendous promise with its BCMA program in immuno-oncology,” said
Dr. Hedley. “I’m excited to have the opportunity to work closely
with the bluebird management team to help bring the promise of
their transformative therapies to patients in need across multiple
products and markets.”
Mary Lynne Hedley, Ph.D., co-founded TESARO, Inc., in 2010 and
since that time, has served as the company’s President and as a
member of its board of directors. Prior to founding TESARO, Dr.
Hedley served as Executive Vice President of Operations and Chief
Scientific Officer of Abraxis BioScience. She served as Executive
Vice President of Eisai Corporation of North America from January
2008 until July 2009, following the company's acquisition of MGI
PHARMA in January 2008. Dr. Hedley served in various positions at
MGI PHARMA from 2004 through its acquisition in January 2008, most
recently as Executive Vice President and Chief Scientific Officer.
Prior to that, Dr. Hedley co-founded and served as the President
and Chief Executive Officer of ZYCOS, which was acquired by MGI
PHARMA in 2004.
Dr. Hedley completed two consecutive postdoctoral fellowships at
Harvard University and earned her doctoral degree in immunology
from the University of Texas, Southwestern Medical Center and her
Bachelor of Science degree in microbiology from Purdue University.
She serves on the Board of Directors of Millendo Therapeutics Inc.
and Youville Place, an assisted living facility. She served on the
Board of Directors of Receptos, Inc. (NASDAQ: RCPT) from April 2014
until August 2015, when Receptos, Inc. was acquired by Celgene
Corporation.
bluebird bio also announced that with Dr. Hedley’s appointment,
John Maraganore, Ph.D. will transition off the Board of Directors.
Dr. Maraganore has been on bluebird bio’s Board since 2012.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the Company’s product candidates and research programs.
Any forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing
clinical trials, the risk of cessation or delay of any of the
ongoing or planned clinical studies and/or our development of our
product candidates, the risk of a delay in the enrollment of
patients in our clinical studies, risks that the current or planned
clinical trials of the LentiGlobin drug product will be
insufficient to support regulatory submissions or marketing
approval in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or
more of our product candidates will not be successfully developed,
approved or commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our annual report on Form 10-K and our most recent quarterly
report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920005316/en/
Investors & Mediabluebird bio, Inc.Elizabeth Pingpank,
617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024